Anti-inflammatory agent 
Welcome,         Profile    Billing    Logout  
 107 Companies  111 Products   111 Products   331 Diseases   454 Trials   27190 News 
662 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Careram (iguratimod) / Eisai, R-Pharm
NCT04928066: The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

Completed
4
100
RoW
Iguratimod, IGU, T-614, Tofacitinib, TF, Pred, Prednisone
Qilu Hospital of Shandong University
Arthritis, Rheumatoid
06/23
07/23
NCT05626348: The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting
4
400
RoW
Iguratimod, IGU, T-614, Methotrexate, MTX, Adalimumab Injection, adalimu, Leflunomide, LEF, Hydroxychloroquine, HCQ
Qilu Hospital of Shandong University
Arthritis, Rheumatoid
06/25
12/26
NCT03855007: The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment

Completed
4
400
RoW
Iguratimod, T-614, MTX, methotrexate, HCQ, Hydroxychloroquine, Pred, Prednisone
Qilu Hospital of Shandong University
Arthritis, Rheumatoid
09/23
10/23
teriflunomide / Generic mfg.
2016-001515-20: nd nd

Ongoing
4
30
Europe
teriflunomide, nd, Film-coated tablet, AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI, genzyme
RELAPSING-REMITTING MULTIPLE SCLEROSIS SCLEROSI MULTIPLA REMITTENTE RECIDIVANTE, ND ND, Diseases [C] - Nervous System Diseases [C10]
 
 
2016-003622-16: The effect of teriflunomide on brain microglial cell activation in multiple sclerosis.

Ongoing
4
30
Europe
Teriflunomide, L04AA31, Film-coated tablet, AUBAGIO
Turku University Hospital, Sanofi-aventis groupe
Multiple sclerosis, MS disease, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2021-003195-13: Importance of monitoring of drugs used in the treatment of multiple sclerosis Význam terapeutického monitorování perorálně podávaných léčiv modifikující průběh choroby (“disease-modifying drugs”) užívaných k léčbě roztroušené sklerózy

Not yet recruiting
4
800
RoW
Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR, Tablet, Capsule, Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-002810-15: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide.

Not yet recruiting
4
11
Europe
Coated tablet, AUBAGIO 14 mg
CHU Brugmann, CHU Brugmann
Multiple sclerosis, treated with teriflunomide, Multiple sclerosis, treated with teriflunomide, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-004331-23: Monitoring of drugs used in the treatment of multiple sclerosis Sledování léčiv užívaných při léčbě roztroušené sklerózy

Not yet recruiting
4
150
RoW
Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR, Tablet, Capsule, hard, Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
TERIS, NCT03122652: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome

Completed
3
125
Europe, RoW
Teriflunomide 14 MG Oral Tablet [Aubagio], Placebo Oral Tablet
Centre Hospitalier Universitaire de Nice, Genzyme, a Sanofi Company
Multiple Sclerosis
02/19
10/22
TERIKIDS, NCT02201108 / 2011-005249-12: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Completed
3
166
Europe, Canada, US, RoW
Teriflunomide, AUBAGIO, HMR1726, Placebo
Genzyme, a Sanofi Company
Multiple Sclerosis
10/19
07/24
2015-002298-39: A national, multi-center study to evaluate the safety of long term treatment with teriflunomide 14 mg once daily in patients with a first clinical episode suggestive of multiple sclerosis in a long-term extension period.

Not yet recruiting
3
12
Europe
TERIFLUNOMIDE, HMR1726, Film-coated tablet, AUBAGIO
CHU de Nice, GENZYME
patient with Clinically isolated syndrome, multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-004505-32: Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients

Ongoing
3
236
Europe
ofatumumab, Glatiramer acetate, Interferon β-1b, Interferon β-1a, Peginterferon β-1a, Teriflunomide, Dimethyl fumarate, OMB157, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Powder and solution for solution for injection, Solution for injection, Solution for infusion in pre-filled syringe, Coated tablet, Gastro-resistant capsule, soft, Kesimpta
Novartis Pharma AG, Novartis Pharma AG
Multiple Sclerosis Sclérose en plaques, Multiple Sclerosis Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-005929-89: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib

Ongoing
3
800
Europe, RoW
remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-005899-36: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib Účinnosť a bezpečnosť remibrutinibu v porovnaní s teriflunomidom u pacientov s relabujúcou roztrúsenou sklerózou

Ongoing
3
800
Europe, RoW
remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
MIRANTIBUS, NCT05385744: An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Completed
3
336
RoW
BCD-132, Teriflunomide
Biocad
Multiple Sclerosis
09/22
09/23
EVOLUTION RMS1, NCT04338022 / 2019-004972-20: Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Terminated
3
1124
Europe, Canada, US, RoW
Evobrutinib, M2951, Placebo (match to Teriflunomide), Teriflunomide, Placebo (match to Evobrutinib)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
evolutionRMS 2, NCT04338061 / 2019-004980-36: Study of Evobrutinib in Participants With RMS

Terminated
3
1166
Europe, Canada, US, RoW
Teriflunomide, Evobrutinib, M2951
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
FREXALT, NCT06141473: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Sanofi
Multiple Sclerosis
05/27
05/27
NCT06372145: A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Recruiting
3
2500
Europe, Canada, Japan, US, RoW
Tolebrutinib, SAR442168, Placebo, Teriflunomide, Aubagio
Sanofi
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
04/29
04/29
GEMINI 2, NCT04410991 / 2020-000644-55: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Completed
3
899
Europe, Canada, US, RoW
Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Sanofi
Relapsing Multiple Sclerosis
07/24
07/24
GEMINI 1, NCT04410978: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Hourglass Jan 2023 - Dec 2023 : Data from GEMINI 1 trial for multiple sclerosis
Completed
3
974
Europe, Canada, Japan, US, RoW
Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Sanofi
Relapsing Multiple Sclerosis
07/24
07/24
TWINS, NCT06663189: Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over ( : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Not yet recruiting
3
200
Europe
treatment withdrawal, Usual DMT continuation, MRI, Quality of Life questionnaires, Disability evaluation tests
University Hospital, Strasbourg, France, Ministry of Health, France
Relapsing-remitting Multiple Sclerosis (RRMS)
01/27
06/29
STHENOS, NCT04788615 / 2020-004505-32: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Active, not recruiting
3
185
Europe
Ofatumumab, OMB157, First line DMT, Glatiramer acetate or Interferon or Peg-Interferon beta-1a or Teriflunomide or Dimethyl fumarate or Diroximel fumarate
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis
11/25
02/26
FENhance, NCT04586010 / 2019-004857-10: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Active, not recruiting
3
746
Europe, US, RoW
Fenebrutinib, Teriflunomide, Placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
10/25
11/25
FENhance 2, NCT04586023 / 2020-001168-28: Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Active, not recruiting
3
751
Europe, Canada, US, RoW
Fenebrutinib, Teriflunomide, Placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
10/25
11/25
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
NCT04056897: Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Completed
2
271
RoW
BCD-132, 125 mg, Teriflunomide, Placebo, BCD-132, 500 mg
Biocad
Multiple Sclerosis
07/20
01/22
2020-002307-18: A study on the efficacy and tolerability of a 14-day treatment with teriflunomide 14 mg tablets vs. placebo in subjects with well-controlled coeliac disease undergoing a 3-day gluten challenge

Not yet recruiting
2
15
Europe
Aubagio, Capsule, Aubagio
Oslo University Hospital, Oslo University Hospital
Coeliac disease, Coeliac disease, Diseases [C] - Immune System Diseases [C20]
 
 
NCT06190145: Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
40
RoW
Teriflunomide, AUBAGIO
Peking University People's Hospital
Immune Thrombocytopenia
10/24
06/25
NCT06176911: The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
124
RoW
Teriflunomide, AUBAGIO, Danazol
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
12/24
07/25
NCT06176235: Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

Recruiting
2
132
RoW
Teriflunomide, AUBAGIO, Dexamethasone
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
12/24
05/25
MS-tolDC_2, NCT06715605: A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded TolDC As Treatment for MS

Not yet recruiting
2
48
Europe
tolerogenic dendritic cells (tolDC), Standard-of-care
University Hospital, Antwerp, Hospital Germans Tríes i Pujol de Badalona
Multiple Sclerosis
04/25
10/27
NCT04806737 / 2020-002307-18: Teriflunomide Vs. Placebo During Gluten Challenge in Celiac Disease

Completed
1/2
15
Europe
Teriflunomide Oral Tablet, Gluten challenge
Oslo University Hospital, Oslo University Hospital
Celiac Disease
10/22
12/23
NCT04799288: Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

Recruiting
1/2
24
US
Teriflunomide
National Institute of Neurological Disorders and Stroke (NINDS)
HAM/TSP
08/25
08/25
NCT06705608: Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

Completed
N/A
4000
NA
Fingolimod, Natalizumab, Dimethyl fumarate (DMF), Alemtuzumab, Teriflunomide
University of British Columbia
Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell, Multiple Sclerosis (MS) - Relapsing-remitting
12/20
12/20
Clad'Action, NCT04821596: Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis

Recruiting
N/A
75
Europe
biological collection
University Hospital, Rouen
Multiple Sclerosis
08/21
12/21
NCT05075499: Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

Recruiting
N/A
70
RoW
COVID-19 vaccination, Blood withdrawn
Sheba Medical Center, Sanofi
Multiple Sclerosis
12/21
09/22
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT05811949: Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.

Completed
N/A
52
Europe
Dimethyl Fumarate 240 MG [Tecfidera]
IRCCS Centro Neurolesi Bonino Pulejo
Multiple Sclerosis
10/22
06/23
AUBACOG, NCT03768648: Cognition and MRI Markers in MS Patients With Aubagio® Treatment

Completed
N/A
75
Europe
Clinical assessment, Ecological evaluation, Neuropsychological evaluation, Psychological evaluation, MRI Evaluation
University Hospital, Bordeaux, Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
02/23
02/23
NCT03198351: An Observational Study on Teriflunomide-exposed Pregnancies

Completed
N/A
220
Canada, US
Teriflunomide (HMR1726), Aubagio
Sanofi
Multiple Sclerosis
06/23
06/23
DOT-MS, NCT04260711: Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis ().

Recruiting
N/A
130
Europe
DMT, Interferon, Glatiramer acetate, Dimethylfumarate, Teriflunomide
VU University Medical Center
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
08/23
01/24
TERIPET, NCT03368677: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression

Active, not recruiting
N/A
26
Europe
Turku University Hospital
Multiple Sclerosis
06/27
12/27
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Completed
N/A
80327
US
Tysabri, Natalizumab BG00002
Biogen
Progressive Multifocal Leukoencephalopathy
12/23
12/23
ULTIMS, NCT05718947: Ultra-high-field Brain MRI in Multiple Sclerosis

Completed
N/A
10
Europe
Brain MRI (3T, 7T, 9.4T)
Zuyderland Medisch Centrum, Scannexus
Multiple Sclerosis
06/24
06/24
FILAXOS, NCT06551519: A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

Recruiting
N/A
900
Europe
ofatumumab, DMT category 1
Novartis Pharmaceuticals
Multiple Sclerosis
09/27
09/27
RESEPTOR 5-HT7, NCT05746845: Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis

Completed
N/A
100
Europe
Blood sample
Centre Hospitalier Régional d'Orléans
Healthy, Multiple Sclerosis
07/24
07/24
TERIFAB-MS, NCT06843382: Teriflunomide and Fatigability in MS

Not yet recruiting
N/A
100
RoW
TC Erciyes University, Karadeniz Technical University, Bursa Yüksek İhtisas Education and Research Hospital, Sakarya University
Multiple Sclerosis
01/27
01/27
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
NCT05112484: Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis

Not yet recruiting
N/A
600
RoW
Measurement of concentrations of orally-used DMDs, Genetic testing, Parameters for routine use of DMDs, Side effects of orally used DMDs
University Hospital Ostrava, University of Ostrava
Multiple Sclerosis
11/25
05/26
STATURE, NCT04676204: Relationship Between Oral DMT Burden and Adherence in MS

Enrolling by invitation
N/A
323
RoW
Cladribine, Mavenclad, Dimethyl fumarate, Tecfidera, Fingolimod, Gilenya, Teriflunomide, Aubagio, Ozanimod, Zeposia, Diroximel fumarate, Vumerity
Monash University
Multiple Sclerosis, Adherence, Medication
11/25
07/26
KRONOS, NCT05776888: Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

Recruiting
N/A
100
Europe
Ofatumumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
08/26
08/26
PROMISE, NCT05962177: Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

Recruiting
N/A
400
Europe
Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests
University Hospital, Montpellier
Multiple Sclerosis
07/28
07/28
NCT05767736: A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Active, not recruiting
N/A
10500
US
Diroximel Fumarate, VUMERITY, BIIB098, Dimethyl Fumarate, Tecfidera, DMF, BG00012, Disease-Modifying Therapies (DMTs)
Biogen
Multiple Sclerosis
12/32
12/32
GEMINI1, NCT04964791: RMS Study of BTK Inhibitor SAR442168

Recruiting
N/A
900
RoW
SAR442168
Peking University Third Hospital
Relapsing Multiple Sclerosis
08/21
08/24
DATE-TCM, NCT05415579: Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine

Not yet recruiting
N/A
2000
NA
Traditional Chinese medicine (TCM)
Dongzhimen Hospital, Beijing
Demyelinating Diseases of the Central Nervous System (DDC)
10/29
05/30
Acetavance (acetaminophen) / Mallinckrodt
NCT03020875: IV vs Oral Acetaminophen in Spine Fusion Perioperative Care

Enrolling by invitation
4
166
US
Ofirmev, Intravenous Acetaminophen, Per Os Acetaminophen
Hospital for Special Surgery, New York, Mallinckrodt
Multimodal Analgesic Approach
03/26
03/26
POPCORN, NCT03677830: Postoperative Pain Control & Relief in Neonates

Terminated
4
11
US
Acetaminophen, Ofirmev 10 MG/ML Injectable Solution, Saline
St. Louis University
Pain, Postoperative, Premature Infant, Opioid Use
03/24
03/24
PANDORA, NCT04093219: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients

Active, not recruiting
3
900
US
IV acetaminophen, ofirmev, Placebo
Beth Israel Deaconess Medical Center, National Institute on Aging (NIA)
Delirium in Old Age, Delirium, Coronary Artery Disease
03/25
03/26
NCT01391962: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Active, not recruiting
2
34
US
Cediranib, AZD2171 maleate, Recentin, AXD2171, Sunitinib, Sutent, SU11248, SU011248, Prochlorperazine, Compro, Promethazine, Phenadoz, Phenergan, Promethegan, Benzodiazepine, Valium, Diazepam, Estazolam, ProSom, Flurazepam, Dalmane, Lorazepam, Ativan, Filgrastim, Neupogen, Sargramostim, Leukine, Lomotil, Diphenoxylate hydrochloride (HCL)/atropine, Loperamide, Imodium, Diamode, Anti-Diarrheal (loperamide), Vitamin B6, Pyridoxine, Aquaphor, Acetaminophen, Tylenol, Ofirmev, FeverAll, Levothyroxine, Synthroid, Tirosint, Unithroid, Warfarin, Coumadin
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
11/23
03/25
NCT06043323: A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Recruiting
2
20
US
Axicabtagene Ciloleucel, Cyclophosphamide, Cytoxan®, Neosar®, Fludarabine phosphate, Prednisone, Diphenhydramine, Benadryl®, Acetaminophen, Tylenol®, Dorcol®, Feverall, Panadol, APAP, N-Acetyl-P-Aminophenol, Paracetamo, Ofirmev™
M.D. Anderson Cancer Center
Follicular Lymphoma
09/26
09/28
NCI-2022-02215, NCT05285813: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Recruiting
2
42
US
Vibecotamab, XmAb14045, Dexamethasone, Decadron, Acetaminophen, Tylenol®, Dorcol®, Feverallâ"¢, Panadol®, APAP, N-Acetyl-P-Aminophenol, Paracetamol, Ofirmevâ"¢, Diphenhydramine, Benadryl®
M.D. Anderson Cancer Center
AML, MDS
12/26
12/26
19-C-0042, NCT03805932: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting
1
18
US
Moxetumomab Pasudotox-tdfk, Lumoxiti, Rituximab, Rituxan, Ruxience, Rituximab-pvvr, Dexamethasone, Ozurdex, Maxidex, DexPak 6 Day, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Nytol, Banophen, Famotidine, Pepcid AC, Pepcid, Acid Controller, Aspirin, Ecotrin, Enteric Coated Aspirin, Buffered Aspirin
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/23
06/25
NCT05211336: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting
1
14
US
Obinutuzumab, Gazyva, Prednisone, Rayos, Deltasone, Prednisone Intensol, Lenalidomide, REVLIMID, Venetoclax, Venclexta, Venclyxto, Ibrutinib, Imbruvica, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Banophen, Nytol, Peg-filgrastim, Neulasta, CT Scan (chest, abdomen, and pelvis), Computed tomography scan, MRI, Magnetic resonance imaging, 18f-FDG-PET, F18-fluorodeoxyglucose-positron emission tomography, PET, Lumbar puncture/Ommaya tap, Bone marrow aspiration/biopsy, EKG, Electrocardiogram
National Cancer Institute (NCI)
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
06/24
06/29
NCT04599634: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Completed
1
11
US
Obinutuzumab, Gazyna, Afutuzumab, GA101, Venetoclax, GDC-0199, ABT-199, RG-7601, Magrolimab, 5F9, GS-4721, ONO-7913, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Banophen, Nytol, Prednisone/prednisolone, Rayos, Deltasone, Prednisone Intensol, Methylprednisolone, Solu-Medrol, Depo-Medrol, Medrol, CT Scan chest/abdomen/pelvis, Computed tomography scan chest/abdomen/pelvis, MRI, Magnetic resonance imaging, 18-FDG-PET, 18F-fluorodeoxyglucose positron emission tomography, Bone Marrow Biopsy, BM Bx, Bone Marrow Aspiration, BM aspiration
National Cancer Institute (NCI)
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
03/24
06/24
NCT02700451: Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes

Completed
N/A
178
US
Ketorolac, Toradol, Acetaminophen, Tylenol, Ofirmev, Placebo, Normal Saline
Hospital for Special Surgery, New York
Lumbar Osteoarthritis, Spondylosis, Lumbar Disc Disease, Spinal Stenosis
12/21
03/23
NCT06326983: Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery

Recruiting
N/A
58
US
Dexmedetomidine, Precedex, Acetaminophen, Ofirmev, Ketorolac, Toradol, Morphine
Boston Children's Hospital
Tonsillitis, Post-operative Nausea and Vomiting (PONV), Emergence Delirium, Opioid Analgesic Adverse Reaction, Anesthesia, Pain
12/25
04/26
Gelclair / Helsinn
GOMS, NCT06897215: A Sequential Cohort Study Exploring GELCLAIR in the Management of Oral Mucositis in Patients Receiving Radical Radiation for Head and Neck Cancer

Not yet recruiting
N/A
48
NA
Hyaluronic acid hydrogel, Gelclair
Nova Scotia Health Authority
Oral Mucositis Due to Radiation
11/25
12/25
diclofenac potassium oral solution / Generic mfg.
2021-001057-31: A study that evaluates the effect of Diclofenac Potassium and Rimegepant as treatment for a acute migraine attack

Not yet recruiting
4
645
Europe
Voltfast, Rimegepant, Powder and solvent for oral suspension, Dispersible tablet
Glostrup Hospital, Danish Headache Center, Danish Headache Center
Migraine, Migraine, Diseases [C] - Nervous System Diseases [C10]
 
 
ATOM, NCT05211154 / 2021-001057-31: Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine

Recruiting
4
645
Europe
Diclofenac Potassium 50Mg/Pkt Oral Pwdr, Voltfast, Rimegepant 75 MG
Danish Headache Center, Danish Headache Center
Migraine With Aura, Migraine Without Aura
12/24
12/25
NCT06731270: Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Not yet recruiting
2
20
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Diclofenac Potassium, Cambia, Cataflam, CGP 45840B, Zipsor, Electronic Health Record Review, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Emory University, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8
01/26
01/27
naproxen ER / Generic mfg.
NCT05087914: Novel Non-opioid Post-surgical Pain Treatment in Females

Withdrawn
2
60
US
Carbidopa-Levodopa (100mg/25mg):, Sinemet, Parcopa, Rytary, Naproxen, Aleve, Anaprox, Naprosyn, Naprelan, Menstridol
Northwestern University, Northwestern Medical Group, National Institutes of Health (NIH)
Acute Pain, Bunionectomy, Toe Fusion
12/23
01/24
sulfasalazine / Generic mfg.
2017-004542-24`ACTRN12621000264886: Severe Psoriatic arthritis – Early intervEntion to control Disease: the SPEED trial

Ongoing
4
315
Europe
Methotrexate, Sulfasalazine, Leflunomide, Humira, N/A, Tablet, Injection, Methotrexate, Salazopyrin EN, Arava, Humira
University of Oxford, NIHR
Physical Inactivity , Poor dietary behaviour , Obesity , Overweight
 
 
ChiCTR2100043373: Clinical study of Hydroxychloroquine Sulfate and sulfasalazine in the treatment of active rheumatoid arthritis

Completed
4
200
 
HCQ(200mg/d)+MTX ;HCQ(400mg/d)+MTX ;HCQ(200mg/d)+SASP+MTX ;SASP+MTX
Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, Project of Shanghai Science Committee
rheumatoid arthritis
 
 
ChiCTR-TRC-11001274: Integrated Traditional Chinese and Western medicine for ankylosing spondylitis

Completed
4
300
 
Qiangji Granule placebo, Sulfasalazine, Ibuprofen ;Qiangji Granule placebo, Sulfasalazine, Ibuprofen
School of Chinese Medicine Southern Medical University; Development and Reform Commission of Guangdong Province, the
ankylosing spondylitis
 
 
ChiCTR-TRC-13002981: Effectiveness and safety of Chinese herbal medicine in low responders in patient population of rheumatoid arthritis under MTX-based conventional therapy

Completed
4
220
 
GTT tablets, 10 mg 3 times a day after meals. Yi Shen Juan Bi (YSJB) ,1 pocket (8 g) 3 times a day after meals ;Methotrexate (MTX)10 mg/week and Sulfasalazine (SSZ),at an initial dose of 0.5 g three times a day in the first week, from the second week the dose was 1.0g twice a day
Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences; None, China Academy of Chinese Medical Sciences Project
rheumatoid arthritis
 
 
2006-006186-16: IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent

Ongoing
4
535
Europe
Methotrexate, Prednisone, Sulfasalazine, hydroxychloroquine, adalimumab, MTX, HCQ, hydroxychloroquine, Humira, hydroxychloroquine, Humira
Leiden University Medical Center, department of rheumatology
rheumatoid arthritis and undifferentiated arthritis
 
 
2006-004419-24: The Use of Sulfasalazine as an Anti-fibrotic in Acute Alcoholic Hepatitis

Ongoing
4
40
Europe
Sulfasalazine, Sulfasalazine, Sulfasalazine
Southampton University Hospitals Trust (R&D)
Acute Alcoholic Hepatitis
 
 
2007-001190-28: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

Ongoing
4
190
Europe
Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine,
King\'s College London
Rheumatoid Arthritis
 
 
2014-003260-20: CHAMP Trial: comparing monotherapy and polytherapy treatment strategies in newly diagnosed juvenile idiopathic arthritis.

Ongoing
4
130
Europe
Sulfasalazine, Hydroxychloroquine, Tablet, Methotrexate, sulfasalazine, Hydroxychloroquine
Leiden University Medical Centre, ZonMw
Juvenile idiopathic arthritis, Juvenile idiopathic arthritis jeugdreuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
TEEMS, NCT03813771 / 2016-002344-16: Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification

Not yet recruiting
4
106
Europe
Benepali, Etanercept, Sulfasalazine, Methotrexate, Hydroxychloroquine
University of Leeds, Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
02/23
02/23
2018-002735-26: A clinical study to test the effects of a apremilast compared to placebo for the treatment of patients with Psoriatic Arthritis with less than 2 years of duration and up to 4 joints involved, despite stable treatment with either non-steroidal anti-inflammatory drugs (ie aspirin, ibuprofen and naproxyn) and /or ≤ 1 non-biologic disease-modifying antirheumatic drugs (methotrexate OR sulfasalazine).

Not yet recruiting
4
330
Europe, RoW
Apremilast, CC-10004, Film-coated tablet, Otezla
Amgen Inc., Celgene Corporation, CELGENE CORPORATION, Amgen Inc, Celgene Corporation, Amgen Inc.
EARLY, OLIGOARTICULAR PSORIATIC ARTHRITIS, Mild form of joint inflammation affecting individuals with the skin disorder, psoriasis., Diseases [C] - Immune System Diseases [C20]
 
 
NCT03739853: Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

Recruiting
4
315
Europe
Methotrexate, Sulfasalazine, Leflunomide, Adalimumab
University of Oxford
Psoriatic Arthritis
08/24
02/25
NCT03254589: Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Completed
4
124
RoW
Methotrexate, Sulfasalazine, Other DMARDs
Flinders University, University of South Australia, medac GmbH
Rheumatoid Arthritis, Stiffness, Aortic, Endothelial Dysfunction, Cardiovascular Risk Factor
12/23
12/23
ChiCTR2300072896: Cost-effectiveness of adalimumab "reduction strategies" in the treatment of rheumatoid arthritis: a multicenter, prospective, real-world observational study

Not yet recruiting
4
1000
 
None ;Adalimumab tapering combined with methotrexate therapy. The recommended dosage of adalimumab is as follows: Adalimumab, 40 mg/2 weeks, subcutaneous injection, reduce the dose after full dose treatment after reaching low disease activity. The dose reduction is carried out as follows: to extend the duration of administration and limiting the maximum duration of administration interval to 6 weeks (it is recommended to extend the duration of administration interval to 3, 4 or 6 weeks). The recommended dose of methotrexate is as follows: Methotrexate, taken orally, 10-30 mg once a week. ;triple therapy is applied. According to the patient's condition and willingness of patients, three traditional synthetic anti-rheumatic drug combination treatment could be applied, including but not limited to: methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, etc. Recommended usage and dosage are as follows: Methotrexate, oral, 10-30 mg each time, once a week; Leflunomide, 10-20 mg once daily; Sulfasalazine, orally, 500 mg-1,000 mg each time, 3-4 times a day; Hydroxychloroquine, orally, 0.2 g to 0.4 g, once a day.
The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, Self-funded
rheumatoid arthritis
 
 
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients with Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

Recruiting
4
286
Europe
Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
University Hospital, Strasbourg, France
Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
03/29
03/29
2006-005104-14: A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma

Ongoing
3
20
Europe
Sulfasalazine, Gemcitabine,
Universitätsklinikum Schleswig-Holstein
Pancreatic ductal adenocarcinoma, non resectable
 
 
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
NCT06134388: Sulfasalazine in Patients With Metastatic Colorectal Cancer

Recruiting
3
50
RoW
Sulfasalazine
Tanta University
Metastatic Colorectal Cancer
09/25
09/26
NCT06060301: Topical Sulfasalazine and Oral Lichen Planus

Active, not recruiting
3
46
RoW
sulfasalazine 500 MG, colosalazine, corticosteroids, kenakort in orabase
Cairo University
Oral Lichen Planus, Topical Sulfasalazine, Corticosteroids
09/24
10/24
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting
3
270
Europe
Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara
University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Withdrawal, Reduction
10/24
10/25
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/27
03/28
ACTRN12621001347853p: Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.

Not yet recruiting
2
38
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic cancer
 
 
ACTRN12621001347853: Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.

Recruiting
2
38
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic cancer
 
 
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Recruiting
2
42
US
Sulfasalazine, Azulfidine, Placebo
Brigham and Women's Hospital
Primary Sclerosing Cholangitis
09/24
11/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Careram (iguratimod) / Eisai, R-Pharm
NCT04928066: The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

Completed
4
100
RoW
Iguratimod, IGU, T-614, Tofacitinib, TF, Pred, Prednisone
Qilu Hospital of Shandong University
Arthritis, Rheumatoid
06/23
07/23
NCT05626348: The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting
4
400
RoW
Iguratimod, IGU, T-614, Methotrexate, MTX, Adalimumab Injection, adalimu, Leflunomide, LEF, Hydroxychloroquine, HCQ
Qilu Hospital of Shandong University
Arthritis, Rheumatoid
06/25
12/26
NCT03855007: The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment

Completed
4
400
RoW
Iguratimod, T-614, MTX, methotrexate, HCQ, Hydroxychloroquine, Pred, Prednisone
Qilu Hospital of Shandong University
Arthritis, Rheumatoid
09/23
10/23
teriflunomide / Generic mfg.
2016-001515-20: nd nd

Ongoing
4
30
Europe
teriflunomide, nd, Film-coated tablet, AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI, genzyme
RELAPSING-REMITTING MULTIPLE SCLEROSIS SCLEROSI MULTIPLA REMITTENTE RECIDIVANTE, ND ND, Diseases [C] - Nervous System Diseases [C10]
 
 
2016-003622-16: The effect of teriflunomide on brain microglial cell activation in multiple sclerosis.

Ongoing
4
30
Europe
Teriflunomide, L04AA31, Film-coated tablet, AUBAGIO
Turku University Hospital, Sanofi-aventis groupe
Multiple sclerosis, MS disease, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2021-003195-13: Importance of monitoring of drugs used in the treatment of multiple sclerosis Význam terapeutického monitorování perorálně podávaných léčiv modifikující průběh choroby (“disease-modifying drugs”) užívaných k léčbě roztroušené sklerózy

Not yet recruiting
4
800
RoW
Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR, Tablet, Capsule, Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-002810-15: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide.

Not yet recruiting
4
11
Europe
Coated tablet, AUBAGIO 14 mg
CHU Brugmann, CHU Brugmann
Multiple sclerosis, treated with teriflunomide, Multiple sclerosis, treated with teriflunomide, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-004331-23: Monitoring of drugs used in the treatment of multiple sclerosis Sledování léčiv užívaných při léčbě roztroušené sklerózy

Not yet recruiting
4
150
RoW
Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR, Tablet, Capsule, hard, Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
TERIS, NCT03122652: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome

Completed
3
125
Europe, RoW
Teriflunomide 14 MG Oral Tablet [Aubagio], Placebo Oral Tablet
Centre Hospitalier Universitaire de Nice, Genzyme, a Sanofi Company
Multiple Sclerosis
02/19
10/22
TERIKIDS, NCT02201108 / 2011-005249-12: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Completed
3
166
Europe, Canada, US, RoW
Teriflunomide, AUBAGIO, HMR1726, Placebo
Genzyme, a Sanofi Company
Multiple Sclerosis
10/19
07/24
2015-002298-39: A national, multi-center study to evaluate the safety of long term treatment with teriflunomide 14 mg once daily in patients with a first clinical episode suggestive of multiple sclerosis in a long-term extension period.

Not yet recruiting
3
12
Europe
TERIFLUNOMIDE, HMR1726, Film-coated tablet, AUBAGIO
CHU de Nice, GENZYME
patient with Clinically isolated syndrome, multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-004505-32: Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients

Ongoing
3
236
Europe
ofatumumab, Glatiramer acetate, Interferon β-1b, Interferon β-1a, Peginterferon β-1a, Teriflunomide, Dimethyl fumarate, OMB157, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Powder and solution for solution for injection, Solution for injection, Solution for infusion in pre-filled syringe, Coated tablet, Gastro-resistant capsule, soft, Kesimpta
Novartis Pharma AG, Novartis Pharma AG
Multiple Sclerosis Sclérose en plaques, Multiple Sclerosis Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-005929-89: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib

Ongoing
3
800
Europe, RoW
remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-005899-36: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib Účinnosť a bezpečnosť remibrutinibu v porovnaní s teriflunomidom u pacientov s relabujúcou roztrúsenou sklerózou

Ongoing
3
800
Europe, RoW
remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
MIRANTIBUS, NCT05385744: An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Completed
3
336
RoW
BCD-132, Teriflunomide
Biocad
Multiple Sclerosis
09/22
09/23
EVOLUTION RMS1, NCT04338022 / 2019-004972-20: Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Terminated
3
1124
Europe, Canada, US, RoW
Evobrutinib, M2951, Placebo (match to Teriflunomide), Teriflunomide, Placebo (match to Evobrutinib)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
evolutionRMS 2, NCT04338061 / 2019-004980-36: Study of Evobrutinib in Participants With RMS

Terminated
3
1166
Europe, Canada, US, RoW
Teriflunomide, Evobrutinib, M2951
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
FREXALT, NCT06141473: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Sanofi
Multiple Sclerosis
05/27
05/27
NCT06372145: A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Recruiting
3
2500
Europe, Canada, Japan, US, RoW
Tolebrutinib, SAR442168, Placebo, Teriflunomide, Aubagio
Sanofi
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
04/29
04/29
GEMINI 2, NCT04410991 / 2020-000644-55: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Completed
3
899
Europe, Canada, US, RoW
Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Sanofi
Relapsing Multiple Sclerosis
07/24
07/24
GEMINI 1, NCT04410978: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Hourglass Jan 2023 - Dec 2023 : Data from GEMINI 1 trial for multiple sclerosis
Completed
3
974
Europe, Canada, Japan, US, RoW
Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Sanofi
Relapsing Multiple Sclerosis
07/24
07/24
TWINS, NCT06663189: Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over ( : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Not yet recruiting
3
200
Europe
treatment withdrawal, Usual DMT continuation, MRI, Quality of Life questionnaires, Disability evaluation tests
University Hospital, Strasbourg, France, Ministry of Health, France
Relapsing-remitting Multiple Sclerosis (RRMS)
01/27
06/29
STHENOS, NCT04788615 / 2020-004505-32: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Active, not recruiting
3
185
Europe
Ofatumumab, OMB157, First line DMT, Glatiramer acetate or Interferon or Peg-Interferon beta-1a or Teriflunomide or Dimethyl fumarate or Diroximel fumarate
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis
11/25
02/26
FENhance, NCT04586010 / 2019-004857-10: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Active, not recruiting
3
746
Europe, US, RoW
Fenebrutinib, Teriflunomide, Placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
10/25
11/25
FENhance 2, NCT04586023 / 2020-001168-28: Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Active, not recruiting
3
751
Europe, Canada, US, RoW
Fenebrutinib, Teriflunomide, Placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
10/25
11/25
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
NCT04056897: Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Completed
2
271
RoW
BCD-132, 125 mg, Teriflunomide, Placebo, BCD-132, 500 mg
Biocad
Multiple Sclerosis
07/20
01/22
2020-002307-18: A study on the efficacy and tolerability of a 14-day treatment with teriflunomide 14 mg tablets vs. placebo in subjects with well-controlled coeliac disease undergoing a 3-day gluten challenge

Not yet recruiting
2
15
Europe
Aubagio, Capsule, Aubagio
Oslo University Hospital, Oslo University Hospital
Coeliac disease, Coeliac disease, Diseases [C] - Immune System Diseases [C20]
 
 
NCT06190145: Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
40
RoW
Teriflunomide, AUBAGIO
Peking University People's Hospital
Immune Thrombocytopenia
10/24
06/25
NCT06176911: The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
124
RoW
Teriflunomide, AUBAGIO, Danazol
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
12/24
07/25
NCT06176235: Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

Recruiting
2
132
RoW
Teriflunomide, AUBAGIO, Dexamethasone
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
12/24
05/25
MS-tolDC_2, NCT06715605: A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded TolDC As Treatment for MS

Not yet recruiting
2
48
Europe
tolerogenic dendritic cells (tolDC), Standard-of-care
University Hospital, Antwerp, Hospital Germans Tríes i Pujol de Badalona
Multiple Sclerosis
04/25
10/27
NCT04806737 / 2020-002307-18: Teriflunomide Vs. Placebo During Gluten Challenge in Celiac Disease

Completed
1/2
15
Europe
Teriflunomide Oral Tablet, Gluten challenge
Oslo University Hospital, Oslo University Hospital
Celiac Disease
10/22
12/23
NCT04799288: Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

Recruiting
1/2
24
US
Teriflunomide
National Institute of Neurological Disorders and Stroke (NINDS)
HAM/TSP
08/25
08/25
NCT06705608: Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

Completed
N/A
4000
NA
Fingolimod, Natalizumab, Dimethyl fumarate (DMF), Alemtuzumab, Teriflunomide
University of British Columbia
Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell, Multiple Sclerosis (MS) - Relapsing-remitting
12/20
12/20
Clad'Action, NCT04821596: Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis

Recruiting
N/A
75
Europe
biological collection
University Hospital, Rouen
Multiple Sclerosis
08/21
12/21
NCT05075499: Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

Recruiting
N/A
70
RoW
COVID-19 vaccination, Blood withdrawn
Sheba Medical Center, Sanofi
Multiple Sclerosis
12/21
09/22
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT05811949: Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.

Completed
N/A
52
Europe
Dimethyl Fumarate 240 MG [Tecfidera]
IRCCS Centro Neurolesi Bonino Pulejo
Multiple Sclerosis
10/22
06/23
AUBACOG, NCT03768648: Cognition and MRI Markers in MS Patients With Aubagio® Treatment

Completed
N/A
75
Europe
Clinical assessment, Ecological evaluation, Neuropsychological evaluation, Psychological evaluation, MRI Evaluation
University Hospital, Bordeaux, Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
02/23
02/23
NCT03198351: An Observational Study on Teriflunomide-exposed Pregnancies

Completed
N/A
220
Canada, US
Teriflunomide (HMR1726), Aubagio
Sanofi
Multiple Sclerosis
06/23
06/23
DOT-MS, NCT04260711: Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis ().

Recruiting
N/A
130
Europe
DMT, Interferon, Glatiramer acetate, Dimethylfumarate, Teriflunomide
VU University Medical Center
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
08/23
01/24
TERIPET, NCT03368677: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression

Active, not recruiting
N/A
26
Europe
Turku University Hospital
Multiple Sclerosis
06/27
12/27
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Completed
N/A
80327
US
Tysabri, Natalizumab BG00002
Biogen
Progressive Multifocal Leukoencephalopathy
12/23
12/23
ULTIMS, NCT05718947: Ultra-high-field Brain MRI in Multiple Sclerosis

Completed
N/A
10
Europe
Brain MRI (3T, 7T, 9.4T)
Zuyderland Medisch Centrum, Scannexus
Multiple Sclerosis
06/24
06/24
FILAXOS, NCT06551519: A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

Recruiting
N/A
900
Europe
ofatumumab, DMT category 1
Novartis Pharmaceuticals
Multiple Sclerosis
09/27
09/27
RESEPTOR 5-HT7, NCT05746845: Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis

Completed
N/A
100
Europe
Blood sample
Centre Hospitalier Régional d'Orléans
Healthy, Multiple Sclerosis
07/24
07/24
TERIFAB-MS, NCT06843382: Teriflunomide and Fatigability in MS

Not yet recruiting
N/A
100
RoW
TC Erciyes University, Karadeniz Technical University, Bursa Yüksek İhtisas Education and Research Hospital, Sakarya University
Multiple Sclerosis
01/27
01/27
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
NCT05112484: Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis

Not yet recruiting
N/A
600
RoW
Measurement of concentrations of orally-used DMDs, Genetic testing, Parameters for routine use of DMDs, Side effects of orally used DMDs
University Hospital Ostrava, University of Ostrava
Multiple Sclerosis
11/25
05/26
STATURE, NCT04676204: Relationship Between Oral DMT Burden and Adherence in MS

Enrolling by invitation
N/A
323
RoW
Cladribine, Mavenclad, Dimethyl fumarate, Tecfidera, Fingolimod, Gilenya, Teriflunomide, Aubagio, Ozanimod, Zeposia, Diroximel fumarate, Vumerity
Monash University
Multiple Sclerosis, Adherence, Medication
11/25
07/26
KRONOS, NCT05776888: Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

Recruiting
N/A
100
Europe
Ofatumumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
08/26
08/26
PROMISE, NCT05962177: Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

Recruiting
N/A
400
Europe
Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests
University Hospital, Montpellier
Multiple Sclerosis
07/28
07/28
NCT05767736: A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Active, not recruiting
N/A
10500
US
Diroximel Fumarate, VUMERITY, BIIB098, Dimethyl Fumarate, Tecfidera, DMF, BG00012, Disease-Modifying Therapies (DMTs)
Biogen
Multiple Sclerosis
12/32
12/32
GEMINI1, NCT04964791: RMS Study of BTK Inhibitor SAR442168

Recruiting
N/A
900
RoW
SAR442168
Peking University Third Hospital
Relapsing Multiple Sclerosis
08/21
08/24
DATE-TCM, NCT05415579: Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine

Not yet recruiting
N/A
2000
NA
Traditional Chinese medicine (TCM)
Dongzhimen Hospital, Beijing
Demyelinating Diseases of the Central Nervous System (DDC)
10/29
05/30
Acetavance (acetaminophen) / Mallinckrodt
NCT03020875: IV vs Oral Acetaminophen in Spine Fusion Perioperative Care

Enrolling by invitation
4
166
US
Ofirmev, Intravenous Acetaminophen, Per Os Acetaminophen
Hospital for Special Surgery, New York, Mallinckrodt
Multimodal Analgesic Approach
03/26
03/26
POPCORN, NCT03677830: Postoperative Pain Control & Relief in Neonates

Terminated
4
11
US
Acetaminophen, Ofirmev 10 MG/ML Injectable Solution, Saline
St. Louis University
Pain, Postoperative, Premature Infant, Opioid Use
03/24
03/24
PANDORA, NCT04093219: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients

Active, not recruiting
3
900
US
IV acetaminophen, ofirmev, Placebo
Beth Israel Deaconess Medical Center, National Institute on Aging (NIA)
Delirium in Old Age, Delirium, Coronary Artery Disease
03/25
03/26
NCT01391962: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Active, not recruiting
2
34
US
Cediranib, AZD2171 maleate, Recentin, AXD2171, Sunitinib, Sutent, SU11248, SU011248, Prochlorperazine, Compro, Promethazine, Phenadoz, Phenergan, Promethegan, Benzodiazepine, Valium, Diazepam, Estazolam, ProSom, Flurazepam, Dalmane, Lorazepam, Ativan, Filgrastim, Neupogen, Sargramostim, Leukine, Lomotil, Diphenoxylate hydrochloride (HCL)/atropine, Loperamide, Imodium, Diamode, Anti-Diarrheal (loperamide), Vitamin B6, Pyridoxine, Aquaphor, Acetaminophen, Tylenol, Ofirmev, FeverAll, Levothyroxine, Synthroid, Tirosint, Unithroid, Warfarin, Coumadin
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
11/23
03/25
NCT06043323: A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Recruiting
2
20
US
Axicabtagene Ciloleucel, Cyclophosphamide, Cytoxan®, Neosar®, Fludarabine phosphate, Prednisone, Diphenhydramine, Benadryl®, Acetaminophen, Tylenol®, Dorcol®, Feverall, Panadol, APAP, N-Acetyl-P-Aminophenol, Paracetamo, Ofirmev™
M.D. Anderson Cancer Center
Follicular Lymphoma
09/26
09/28
NCI-2022-02215, NCT05285813: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Recruiting
2
42
US
Vibecotamab, XmAb14045, Dexamethasone, Decadron, Acetaminophen, Tylenol®, Dorcol®, Feverallâ"¢, Panadol®, APAP, N-Acetyl-P-Aminophenol, Paracetamol, Ofirmevâ"¢, Diphenhydramine, Benadryl®
M.D. Anderson Cancer Center
AML, MDS
12/26
12/26
19-C-0042, NCT03805932: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting
1
18
US
Moxetumomab Pasudotox-tdfk, Lumoxiti, Rituximab, Rituxan, Ruxience, Rituximab-pvvr, Dexamethasone, Ozurdex, Maxidex, DexPak 6 Day, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Nytol, Banophen, Famotidine, Pepcid AC, Pepcid, Acid Controller, Aspirin, Ecotrin, Enteric Coated Aspirin, Buffered Aspirin
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/23
06/25
NCT05211336: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting
1
14
US
Obinutuzumab, Gazyva, Prednisone, Rayos, Deltasone, Prednisone Intensol, Lenalidomide, REVLIMID, Venetoclax, Venclexta, Venclyxto, Ibrutinib, Imbruvica, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Banophen, Nytol, Peg-filgrastim, Neulasta, CT Scan (chest, abdomen, and pelvis), Computed tomography scan, MRI, Magnetic resonance imaging, 18f-FDG-PET, F18-fluorodeoxyglucose-positron emission tomography, PET, Lumbar puncture/Ommaya tap, Bone marrow aspiration/biopsy, EKG, Electrocardiogram
National Cancer Institute (NCI)
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
06/24
06/29
NCT04599634: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Completed
1
11
US
Obinutuzumab, Gazyna, Afutuzumab, GA101, Venetoclax, GDC-0199, ABT-199, RG-7601, Magrolimab, 5F9, GS-4721, ONO-7913, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Banophen, Nytol, Prednisone/prednisolone, Rayos, Deltasone, Prednisone Intensol, Methylprednisolone, Solu-Medrol, Depo-Medrol, Medrol, CT Scan chest/abdomen/pelvis, Computed tomography scan chest/abdomen/pelvis, MRI, Magnetic resonance imaging, 18-FDG-PET, 18F-fluorodeoxyglucose positron emission tomography, Bone Marrow Biopsy, BM Bx, Bone Marrow Aspiration, BM aspiration
National Cancer Institute (NCI)
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
03/24
06/24
NCT02700451: Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes

Completed
N/A
178
US
Ketorolac, Toradol, Acetaminophen, Tylenol, Ofirmev, Placebo, Normal Saline
Hospital for Special Surgery, New York
Lumbar Osteoarthritis, Spondylosis, Lumbar Disc Disease, Spinal Stenosis
12/21
03/23
NCT06326983: Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery

Recruiting
N/A
58
US
Dexmedetomidine, Precedex, Acetaminophen, Ofirmev, Ketorolac, Toradol, Morphine
Boston Children's Hospital
Tonsillitis, Post-operative Nausea and Vomiting (PONV), Emergence Delirium, Opioid Analgesic Adverse Reaction, Anesthesia, Pain
12/25
04/26
Gelclair / Helsinn
GOMS, NCT06897215: A Sequential Cohort Study Exploring GELCLAIR in the Management of Oral Mucositis in Patients Receiving Radical Radiation for Head and Neck Cancer

Not yet recruiting
N/A
48
NA
Hyaluronic acid hydrogel, Gelclair
Nova Scotia Health Authority
Oral Mucositis Due to Radiation
11/25
12/25
diclofenac potassium oral solution / Generic mfg.
2021-001057-31: A study that evaluates the effect of Diclofenac Potassium and Rimegepant as treatment for a acute migraine attack

Not yet recruiting
4
645
Europe
Voltfast, Rimegepant, Powder and solvent for oral suspension, Dispersible tablet
Glostrup Hospital, Danish Headache Center, Danish Headache Center
Migraine, Migraine, Diseases [C] - Nervous System Diseases [C10]
 
 
ATOM, NCT05211154 / 2021-001057-31: Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine

Recruiting
4
645
Europe
Diclofenac Potassium 50Mg/Pkt Oral Pwdr, Voltfast, Rimegepant 75 MG
Danish Headache Center, Danish Headache Center
Migraine With Aura, Migraine Without Aura
12/24
12/25
NCT06731270: Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Not yet recruiting
2
20
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Diclofenac Potassium, Cambia, Cataflam, CGP 45840B, Zipsor, Electronic Health Record Review, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Emory University, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8
01/26
01/27
naproxen ER / Generic mfg.
NCT05087914: Novel Non-opioid Post-surgical Pain Treatment in Females

Withdrawn
2
60
US
Carbidopa-Levodopa (100mg/25mg):, Sinemet, Parcopa, Rytary, Naproxen, Aleve, Anaprox, Naprosyn, Naprelan, Menstridol
Northwestern University, Northwestern Medical Group, National Institutes of Health (NIH)
Acute Pain, Bunionectomy, Toe Fusion
12/23
01/24
sulfasalazine / Generic mfg.
2017-004542-24`ACTRN12621000264886: Severe Psoriatic arthritis – Early intervEntion to control Disease: the SPEED trial

Ongoing
4
315
Europe
Methotrexate, Sulfasalazine, Leflunomide, Humira, N/A, Tablet, Injection, Methotrexate, Salazopyrin EN, Arava, Humira
University of Oxford, NIHR
Physical Inactivity , Poor dietary behaviour , Obesity , Overweight
 
 
ChiCTR2100043373: Clinical study of Hydroxychloroquine Sulfate and sulfasalazine in the treatment of active rheumatoid arthritis

Completed
4
200
 
HCQ(200mg/d)+MTX ;HCQ(400mg/d)+MTX ;HCQ(200mg/d)+SASP+MTX ;SASP+MTX
Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, Project of Shanghai Science Committee
rheumatoid arthritis
 
 
ChiCTR-TRC-11001274: Integrated Traditional Chinese and Western medicine for ankylosing spondylitis

Completed
4
300
 
Qiangji Granule placebo, Sulfasalazine, Ibuprofen ;Qiangji Granule placebo, Sulfasalazine, Ibuprofen
School of Chinese Medicine Southern Medical University; Development and Reform Commission of Guangdong Province, the
ankylosing spondylitis
 
 
ChiCTR-TRC-13002981: Effectiveness and safety of Chinese herbal medicine in low responders in patient population of rheumatoid arthritis under MTX-based conventional therapy

Completed
4
220
 
GTT tablets, 10 mg 3 times a day after meals. Yi Shen Juan Bi (YSJB) ,1 pocket (8 g) 3 times a day after meals ;Methotrexate (MTX)10 mg/week and Sulfasalazine (SSZ),at an initial dose of 0.5 g three times a day in the first week, from the second week the dose was 1.0g twice a day
Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences; None, China Academy of Chinese Medical Sciences Project
rheumatoid arthritis
 
 
2006-006186-16: IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent

Ongoing
4
535
Europe
Methotrexate, Prednisone, Sulfasalazine, hydroxychloroquine, adalimumab, MTX, HCQ, hydroxychloroquine, Humira, hydroxychloroquine, Humira
Leiden University Medical Center, department of rheumatology
rheumatoid arthritis and undifferentiated arthritis
 
 
2006-004419-24: The Use of Sulfasalazine as an Anti-fibrotic in Acute Alcoholic Hepatitis

Ongoing
4
40
Europe
Sulfasalazine, Sulfasalazine, Sulfasalazine
Southampton University Hospitals Trust (R&D)
Acute Alcoholic Hepatitis
 
 
2007-001190-28: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

Ongoing
4
190
Europe
Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine,
King\'s College London
Rheumatoid Arthritis
 
 
2014-003260-20: CHAMP Trial: comparing monotherapy and polytherapy treatment strategies in newly diagnosed juvenile idiopathic arthritis.

Ongoing
4
130
Europe
Sulfasalazine, Hydroxychloroquine, Tablet, Methotrexate, sulfasalazine, Hydroxychloroquine
Leiden University Medical Centre, ZonMw
Juvenile idiopathic arthritis, Juvenile idiopathic arthritis jeugdreuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
TEEMS, NCT03813771 / 2016-002344-16: Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification

Not yet recruiting
4
106
Europe
Benepali, Etanercept, Sulfasalazine, Methotrexate, Hydroxychloroquine
University of Leeds, Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
02/23
02/23
2018-002735-26: A clinical study to test the effects of a apremilast compared to placebo for the treatment of patients with Psoriatic Arthritis with less than 2 years of duration and up to 4 joints involved, despite stable treatment with either non-steroidal anti-inflammatory drugs (ie aspirin, ibuprofen and naproxyn) and /or ≤ 1 non-biologic disease-modifying antirheumatic drugs (methotrexate OR sulfasalazine).

Not yet recruiting
4
330
Europe, RoW
Apremilast, CC-10004, Film-coated tablet, Otezla
Amgen Inc., Celgene Corporation, CELGENE CORPORATION, Amgen Inc, Celgene Corporation, Amgen Inc.
EARLY, OLIGOARTICULAR PSORIATIC ARTHRITIS, Mild form of joint inflammation affecting individuals with the skin disorder, psoriasis., Diseases [C] - Immune System Diseases [C20]
 
 
NCT03739853: Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

Recruiting
4
315
Europe
Methotrexate, Sulfasalazine, Leflunomide, Adalimumab
University of Oxford
Psoriatic Arthritis
08/24
02/25
NCT03254589: Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Completed
4
124
RoW
Methotrexate, Sulfasalazine, Other DMARDs
Flinders University, University of South Australia, medac GmbH
Rheumatoid Arthritis, Stiffness, Aortic, Endothelial Dysfunction, Cardiovascular Risk Factor
12/23
12/23
ChiCTR2300072896: Cost-effectiveness of adalimumab "reduction strategies" in the treatment of rheumatoid arthritis: a multicenter, prospective, real-world observational study

Not yet recruiting
4
1000
 
None ;Adalimumab tapering combined with methotrexate therapy. The recommended dosage of adalimumab is as follows: Adalimumab, 40 mg/2 weeks, subcutaneous injection, reduce the dose after full dose treatment after reaching low disease activity. The dose reduction is carried out as follows: to extend the duration of administration and limiting the maximum duration of administration interval to 6 weeks (it is recommended to extend the duration of administration interval to 3, 4 or 6 weeks). The recommended dose of methotrexate is as follows: Methotrexate, taken orally, 10-30 mg once a week. ;triple therapy is applied. According to the patient's condition and willingness of patients, three traditional synthetic anti-rheumatic drug combination treatment could be applied, including but not limited to: methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, etc. Recommended usage and dosage are as follows: Methotrexate, oral, 10-30 mg each time, once a week; Leflunomide, 10-20 mg once daily; Sulfasalazine, orally, 500 mg-1,000 mg each time, 3-4 times a day; Hydroxychloroquine, orally, 0.2 g to 0.4 g, once a day.
The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, Self-funded
rheumatoid arthritis
 
 
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients with Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

Recruiting
4
286
Europe
Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
University Hospital, Strasbourg, France
Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
03/29
03/29
2006-005104-14: A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma

Ongoing
3
20
Europe
Sulfasalazine, Gemcitabine,
Universitätsklinikum Schleswig-Holstein
Pancreatic ductal adenocarcinoma, non resectable
 
 
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
NCT06134388: Sulfasalazine in Patients With Metastatic Colorectal Cancer

Recruiting
3
50
RoW
Sulfasalazine
Tanta University
Metastatic Colorectal Cancer
09/25
09/26
NCT06060301: Topical Sulfasalazine and Oral Lichen Planus

Active, not recruiting
3
46
RoW
sulfasalazine 500 MG, colosalazine, corticosteroids, kenakort in orabase
Cairo University
Oral Lichen Planus, Topical Sulfasalazine, Corticosteroids
09/24
10/24
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting
3
270
Europe
Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara
University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Withdrawal, Reduction
10/24
10/25
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/27
03/28
ACTRN12621001347853p: Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.

Not yet recruiting
2
38
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic cancer
 
 
ACTRN12621001347853: Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.

Recruiting
2
38
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic cancer
 
 
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Recruiting
2
42
US
Sulfasalazine, Azulfidine, Placebo
Brigham and Women's Hospital
Primary Sclerosing Cholangitis
09/24
11/24
 

Download Options